Elevate Capital Advisors LLC Sells 36,236 Shares of Roivant Sciences Ltd. $ROIV

Key Points

• Elevate Capital Advisors cut its stake in Roivant Sciences (NASDAQ:ROIV) by 31.8% in Q4, selling 36,236 shares and retaining 77,545 shares valued at $1.683 million.
• Several institutions materially reshaped positions—most notably Assenagon Asset Management boosted its holding to 6,937,112 shares (a 11,507.5% increase) worth about $150.5 million, while Marshall Wace, Perceptive, Orbimed and Rubric also added large stakes; institutional ownership stands at ~64.76%.
• Insiders have been net sellers recently: Frank Torti sold 587,390 shares for ~$16.16 million, and insiders disposed of ~4,795,624 shares totaling about $129,232,136 over the past 90 days, with insiders now owning 10.8% of the company.

Elevate Capital Advisors LLC cut its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 31.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 77,545 shares of the company's stock after selling 36,236 shares during the quarter. Elevate Capital Advisors LLC's holdings in Roivant Sciences were worth $1,683,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in ROIV. Assenagon Asset Management S.A. grew its holdings in shares of Roivant Sciences by 11,507.5% during the 4th quarter. Assenagon Asset Management S.A. now owns 6,937,112 shares of the company's stock valued at $150,535,000 after purchasing an additional 6,877,348 shares during the last quarter. Perceptive Advisors LLC bought a new stake in shares of Roivant Sciences during the 2nd quarter valued at approximately $37,546,000. Marshall Wace LLP grew its holdings in shares of Roivant Sciences by 316.5% during the 3rd quarter. Marshall Wace LLP now owns 3,978,001 shares of the company's stock valued at $60,187,000 after purchasing an additional 3,022,851 shares during the last quarter. Orbimed Advisors LLC bought a new stake in shares of Roivant Sciences during the 2nd quarter valued at approximately $31,324,000. Finally, Rubric Capital Management LP grew its holdings in shares of Roivant Sciences by 14.7% during the 2nd quarter. Rubric Capital Management LP now owns 20,370,336 shares of the company's stock valued at $229,574,000 after purchasing an additional 2,603,260 shares during the last quarter. 64.76% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Citigroup lifted their price target on shares of Roivant Sciences from $26.00 to $35.00 and gave the company a "buy" rating in a report on Tuesday, February 10th. Sanford C. Bernstein initiated coverage on shares of Roivant Sciences in a report on Friday, March 20th. They set an "outperform" rating and a $35.00 target price on the stock. Guggenheim boosted their target price on shares of Roivant Sciences from $28.00 to $30.00 and gave the stock a "buy" rating in a report on Monday, February 9th. Leerink Partners boosted their target price on shares of Roivant Sciences from $29.00 to $32.00 and gave the stock an "outperform" rating in a report on Monday, December 15th. Finally, Weiss Ratings lowered shares of Roivant Sciences from a "hold (c-)" rating to a "sell (d)" rating in a report on Monday, February 9th. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $29.50.

Insider Activity

In other news, insider Frank Torti sold 587,390 shares of the business's stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $27.51, for a total value of $16,159,098.90. Following the transaction, the insider owned 13,736,547 shares in the company, valued at approximately $377,892,407.97. The trade was a 4.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Jennifer Humes sold 13,538 shares of the business's stock in a transaction that occurred on Wednesday, April 8th. The stock was sold at an average price of $28.37, for a total transaction of $384,073.06. Following the completion of the transaction, the chief accounting officer owned 84,191 shares in the company, valued at $2,388,498.67. This trade represents a 13.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 4,795,624 shares of company stock worth $129,232,136. Company insiders own 10.80% of the company's stock.

Roivant Sciences Price Performance

ROIV opened at $28.21 on Friday. Roivant Sciences Ltd. has a fifty-two week low of $9.57 and a fifty-two week high of $30.33. The firm has a market capitalization of $20.19 billion, a price-to-earnings ratio of -24.11 and a beta of 1.20. The company's 50 day moving average price is $27.40 and its two-hundred day moving average price is $22.69.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.